Supriya Lifescience Limited confirmed its 11% YoY revenue growth for Q3 FY26, reaching INR 206 crores, driven by robust exports (82% of revenue). Management reiterated confidence in achieving the full-year 20% annual revenue growth guidance, expecting a strong Q4. Key milestones include the capitalization of the Ambernath facility in Q4 FY26 and continued progress in scaling up the cardiovascular and ADHD product launches.
Q3 FY26 Financial Performance Highlights
Supriya Lifescience reported its Unaudited Financial Results for the third quarter of FY26 (ending December 31, 2025). Revenue from operations stood at INR 206 crores, marking an 11% year-on-year growth, primarily fueled by robust demand across its portfolio. The management highlighted strong execution, achieving an EBITDA margin of 34.9% and a PAT margin of 24.1% for the quarter.
For the 9 months ended FY26 (9MFY26), revenue grew 8% YoY to INR 551 crores, with EBITDA margins maintained at 36%. PAT for the 9M stood at INR 135 crores.
Growth Drivers and Guidance Reaffirmation
Management reiterated its guidance of approximately 20% annual revenue growth and EBITDA margins of 33% to 35% for the full year. They noted that a significant portion of this growth is anticipated in Q4 FY26 due to shipment delays from mid-December holidays in key export markets (LatAm and Europe) shifting into the final quarter.
Looking ahead to FY27, the company expects to achieve the INR 1,000 crores revenue milestone, driven by three key areas:
- Scaling up the existing product basket through increased regulatory filings (CEPs and USDMFs) in regulated markets.
- The introduction of 3 to 4 new products annually.
- Revenue contribution from the newly commissioned Ambernath facility starting in the next fiscal year.
Operational and Manufacturing Updates
The Ambernath facility, crucial for the CDMO segment, is ready for capitalization, scheduled for Q4 FY26. This site will focus on finished formulations, including the launch of liquid anaesthetics.
Regarding the ATS-8 product (a segment where China has a strong presence), management stated they are not seeking the entire market share. Instead, they will focus on capturing 250 to 300 tons to cater to customers prioritizing USFDA and EU GMP quality, confident this volume can be realized fully by FY27.
Backward integration remains a strategic focus, with 74% of revenues already benefiting from this initiative in Q3 FY26. The conversion process for backward integration of ATS-3 to ATS-5 for ATS-8 production is expected to commercialize by the next month.
Capital Expenditure and Future Projects
Capex for 9MFY26 was INR 71 crores, largely spent on the Ambernath facility. The company expects capex to conclude around INR 15 crores for the remainder of FY26, focusing on maintenance and minor projects.
In terms of new facility planning, the company is considering ground-breaking for Patalganga, which might require an additional INR 40 to 50 crores in the coming year, potentially involving a new formulation or API facility looking towards FY29.
CDMO/CMO Pipeline
The combined goal for new product launches plus CMO/CDMO revenue contribution is set at approximately 20% over the next two years. The revenue from the Ambernath CMO business is expected to see its full impact starting in FY27, pending the completion of the EU audit (expected in Q1 FY27) and subsequent USFDA audits.
Management also confirmed successful filings for Sevoflurane and CVS products DMF/CEP during Q3.
Source: BSE
